March 16th 2025
Puxitatug samrotecan was well tolerated in patients with advanced or metastatic endometrial cancer.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases
View More
Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma
View More
Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies
View More
Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma
View More
Endometriosis/Adenomyosis Status Not an Independent Predictor of Survival in Endometrial Cancer
April 9th 2022Although patients with endometrial cancer who had histologically confirmed endometriosis/adenomyosis achieved better overall survival than those without, the benefit was linked to stage, grade, age, and histological subtype.
Maintenance Selinexor Decreases Risk of Progression for Advanced or Recurrent Endometrial Cancer
March 18th 2022Results presented at an ESMO Virtual Plenary in March 2022 show that maintenance therapy with selinexor decreased the risk of progression or death for patients with advanced or recurrent endometrial cancer.
New Phase 3 Endometrial Cancer Trial Planned for Selinexor After Talks With FDA
March 3rd 2022Topline findings from the phase 3 SIENDO trial did not appear to likely support a supplemental new drug application use of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer, prompting the creation of a new phase 3 trial to support a future submission.
Phase 2 ENPAC Trial Shows Feasibility of Enzalutamide Triplet in Endometrioid Endometrial Cancer
March 25th 2021The androgen receptor inhibitor enzalutamide, an approved therapy for certain types of prostate cancer, has shown activity for the treatment of patients with recurrent or advanced endometrioid endometrial cancer.
Addition of Olaparib to Cediranib Does Not Induce Superior Efficacy in Advanced Endometrial Cancer
March 22nd 2021The combination of cediranib and olaparib demonstrated modest efficacy in patients with recurrent, metastatic, or persistent endometrial cancer; however, this was not significantly different compared to cediranib alone.
Pembrolizumab/Lenvatinib Combo Shows Survival Benefit in Advanced Endometrial Cancer
March 19th 2021Following a prior announcement that the phase 3 KEYNOTE-775 trial met both primary end points of progression-free and overall survival benefit, data for the pembrolizumab/lenvatinib combination were presented at the Society of Gynecologic Oncology 2021 Annual Meeting on Women’s Cancer.
Study Suggests NACT to be Important Treatment Option for Metastatic Endometrial Cancer
December 27th 2020“These findings suggest that similar to its benefits in ovarian cancer, NACT could potentially lower perioperative morbidity and may serve as an important treatment option among women with metastatic endometrial cancer,” the study authors wrote.
Phase 3 KEYNOTE-775/Study 309 Trial Meets Dual Primary End Points in Advanced Endometrial Cancer
December 16th 2020The pivotal phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of pembrolizumab (Keytruda) plus lenvatinib (Lenvima) met its dual primary end points of overall and progression-free survival in patients with advanced endometrial cancer.